Jove
Visualize
Contact Us

Related Concept Videos

Menopause01:28

Menopause

5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

7.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.4K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.1K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.1K
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

2.4K
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
2.4K
Signs of Puberty01:27

Signs of Puberty

1.8K
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.8K
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

6.1K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Young onset dementia: enhancing the diagnostic process and post-diagnosis support.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2026
Same journal

Effect of artificial intelligence on nursing documentation and patient safety.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2026
Same journal

Strategies for responding to anger from patients, relatives and carers.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2026
Same journal

Nurses' role in detecting early and subtle signs of patient deterioration in acute hospitals.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2026
Same journal

Pulse oximetry: exploring its role, limitations and challenges in clinical practice.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2026
Same journal

Anorexia nervosa: identification and management by non-specialist nurses.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 14, 2026

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
05:32

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model

Published on: August 11, 2023

2.7K

Oestrogen levels could be affected.

Ros Mason1

  • 1Brighton.

Nursing Standard (Royal College of Nursing (Great Britain) : 1987)
|September 30, 2016
PubMed
Summary
This summary is machine-generated.

Oestrogen replacement prevents bone loss after menopause. This study questions whether the bone-protective effects of tamoxifen, an antioestrogen, have been communicated to women in clinical trials.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Related Experiment Videos

Last Updated: Mar 14, 2026

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
05:32

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model

Published on: August 11, 2023

2.7K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Bone Metabolism

Background:

  • Randomised trials indicate oestrogen replacement therapy (ERT) significantly prevents post-menopause bone loss.
  • Tamoxifen, an antioestrogen agent, is being investigated in clinical trials.

Purpose of the Study:

  • To determine if the potential osteoporotic benefits of tamoxifen have been adequately explained to women participating in tamoxifen trials.
  • To ensure informed consent regarding bone health implications for trial participants.

Main Methods:

  • Review of information provided to participants in tamoxifen trials.
  • Assessment of communication regarding the antioestrogen effects of tamoxifen on bone density.

Main Results:

  • The abstract does not contain specific results from the tamoxifen trials.
  • It raises a question about the disclosure of tamoxifen's osteoporotic value to trial volunteers.

Conclusions:

  • There is a need to ensure women in tamoxifen trials are fully informed about its effects on bone health.
  • Clarification is required on whether the bone-sparing properties of tamoxifen are communicated during the consent process.